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ABSTRACT
The existing body of literature focuses on the onset of panic disorders or other side
effects as an association with cannabis use, but does little to address how possible concomitant
cannabis use affects symptom presentation in already-diagnosed patients. The present project
aims to take a closer look at adults with a lifetime history of DSM-5 diagnosed anxiety disorders,
their prescribed (non-cannabis) medication use, cannabis use frequency, and associated symptom
severity.
In general, we find that cannabis use is associated with higher panic-anxiety symptom
severity across panic disorder without agoraphobia, generalized anxiety disorder, and people
with combined anxious-distress diagnoses, after controlling for prescription medication status
and professional help seeking. However, the difference between users and non-users is often
small and not necessarily clinically relevant: only 1 or 2 symptoms. Worth noting is that we
found no dose-response relationship for frequency of cannabis use. Being an infrequent user is
not significantly different than being a daily user in terms of unique symptom presentation. This
means that increasingly higher cannabis use does not necessarily induce increasingly more
severe anxiety or distress. Rather, it seems that once an individual’s cannabis use crosses over a
certain threshold, symptom presentation increases. For some disorders, this is an all-or-none
phenomenon; any cannabis use is associated with more severe symptoms than staying abstinent.
For others, only daily users present with higher symptoms than non-users. The sole divergence to
this conclusion is that panic without agoraphobia patients who use infrequently seem to have
more severe symptoms than non-users and daily users.

2

ACKNOWLEDGMENTS
Dr. Mayur Desai, and Dr. Ilan Harpaz-Rotem for their reading and much-needed advice!
Dr. Bradley Kerridge and the National Institutes of Health for their graciousness in providing
access to the NESARC-III dataset

3

TABLE OF CONTENTS
TITLE .......................................................................................................................................................... 1
ABSTRACT ................................................................................................................................................. 2
ACKNOWLEDGMENTS .......................................................................................................................... 3
TABLE OF CONTENTS ........................................................................................................................... 4
LIST OF TABLES ...................................................................................................................................... 5
Table 1. Sample Description .................................................................................................................... 5
Table 2. Unadjusted association between cannabis use frequency and symptom severity category for
each disorder ............................................................................................................................................. 6
Table 3. Unadjusted ordinal logistic regression model for association between cannabis use frequency
and increasing levels of symptom severity (zero-mild, moderate, high and severe) ................................ 7
Table 4. Adjusted ordinal logistic regression model for relationship between cannabis use frequency
and increasing symptom severity categories (zero/none, low, moderate, and severe) .............................. 8
Table 5. Unadjusted multiple linear regression model for relationship between ln(past year symptom
count) and cannabis use frequency ......................................................................................................... 11
Table 6. Adjusted multiple linear regression model for relationship between ln(past year symptom
count) and cannabis use frequency (N= 4689)........................................................................................ 12
BACKGROUND & RATIONALE .......................................................................................................... 15
METHODS ................................................................................................................................................ 16
Survey Instrument ................................................................................................................................ 16
Study Population ................................................................................................................................... 17
Measures ................................................................................................................................................ 17
Independent Variables ........................................................................................................................ 17
Dependent Variables ........................................................................................................................... 19
Data Analysis ......................................................................................................................................... 20
χ2 Tests ................................................................................................................................................ 20
Ordinal Logistic Regression ............................................................................................................... 20
Multiple Linear Regression................................................................................................................. 20
Statistical Plan ....................................................................................................................................... 21
RESULTS .................................................................................................................................................. 21
DISCUSSION ............................................................................................................................................ 26
REFERENCES .......................................................................................................................................... 30

4

LIST OF TABLES
Table 1. Sample Description
Characteristic

Cannabis use within the
last 12 months
No
Yes
Cannabis use frequency
No use
Monthly/weekly
Daily/near daily
Prescription medication
for the affected anxiety
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social
worker, or any other
professional
No
Yes
Race/ethnicity
White
Black
American Indian
/Alaska Native
Asian/ Pacific Islander
Hispanic (any race)
Age (years), mean ± SD
Age (years) at first use of
marijuana, mean ± SD
Sex
Female
Male
Education
Less than high school
High school graduate
At least some college
up to a Bachelor’s
At least some graduate
studies
Marital status
Never married

Panic
Disorder
Without
Agoraphobia

Panic
Disorder
With
Agoraphobia

(N=1255)

(N=2708)

(N=1451)

(N=362)

N (%)*

N (%)*

N (%)*

N (%)*

1215 (83.85)
234 (16.15)

284 (78.45)
78 (21.55)

1024 (81.59) 2285 (84.38)
230 (18.33) 420 (15.51)

3948 (84.20)
737 (15.72)

1215 (83.74)
120 (8.27)
113 (7.79)

284 (78.45)
49 (13.54)
29 (8.01)

1024 (81.59) 2285 (84.38)
133 (10.60) 224 (8.27)
95 (7.57)
193 (7.13)

3948 (84.20)
411 (8.77)
322 (6.87)

608 (41.90)
838 (57.75)

70 (19.34)
290 (80.11)

852 (67.89)
400 (31.87)

2040 (75.33)
666 (24.59)

2480 (52.89)
2191 (46.73)

994 (68.50)
455 (31.36)

162 (44.75)
200 (55.25)

981 (78.17)
274 (21.83)

2244 (82.87)
464 (17.13)

3737 (79.70)
951 (20.28)

962 (66.30)
208 (14.33)

247 (68.23)
48 (13.26)

863 (68.76)
151 (12.03)

1794 (66.25)
413 (15.25)

3091 (65.92)
697 (14.86)

41 (2.83)
25 (1.72)
215 (14.82)
43.63±14.56

16 (4.42)
3 (0.83)
48 (13.26)
42.20±13.85

35 (2.79)
20 (1.59)
186 (14.82)
44.04±16.60

58 (2.14)
75 (2.77)
368 (13.59)
47.09±15.54

107 (2.28)
111 (2.37)
683 (14.57)
45.72± 15.93

16.76±5.43

16.04±4.33

16.98±5.45

17.63±5.53

17.40±6.41

1042 (71.81)
409 (28.19)

277 (76.52)
85 (23.48)

801 (63.82)
454 (36.18)

1836 (67.80)
872 (32.20)

3186 (67.95)
1503 (32.05)

212 (14.61)
375 (25.84)

58 (16.02)
104 (28.73)

191 (15.22)
378 (30.12)

346 (12.78)
673 (24.85)

661 (14.10)
1211 (25.83)

703 (48.45)

166 (45.86)

572 (45.58)

1279 (47.23)

2220 (47.34)

161 (11.10)

34 (9.39)

114 (9.08)

410 (15.14)

597 (12.73)

341 (23.50)

103 (28.45)

374 (29.80)

625 (23.08)

1167 (24.89)
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Social
Anxiety
Disorder

Generalized
Anxiety
Disorder

Total N (%)*

Married or living with
someone as if married
Widowed
Separated or divorced
Number of comorbidities
1
2
3

620 (42.73)
86 (5.93)
404 (27.84)

150 (41.44)
17 (4.70)
92 (25.41)

511 (40.72)
86 (6.85)
284 (22.63)

1149 (42.43)
226 (8.35)
708 (26.14)

1983 (42.29)
354 (7.55)
1185 (25.27)

935 (64.44)
407 (28.05)
109 (7.51)

125 (34.53)
137 (37.85)
100 (27.62)

619 (49.32)
427 (34.02)
209 (16.65)

1820 (67.21)
679 (25.07)
209 (7.72)

3499 (74.62)
825 (17.59)
209 (4.46)

*may not add up to 100% due to some missing values or overlap in multiple comorbidities. Also,
panic disorder alone and panic disorder with agoraphobia are mutually exclusive diagnoses.
Table 2. Unadjusted association between cannabis use frequency and symptom severity category
for each disorder
Disorder

N
(total)

Cannabis Use
Frequency

Panic
Disorder

1215
120

No use
Monthly or
weekly
Daily or near daily

113
(1451)
Panic
284
Disorder
49
with
Agoraphobia 29
(362)
Social
1024
Anxiety
133
Disorder
95
(1252)
Generalized 2285
Anxiety
224
Disorder
193
(2702)
Anxious3948
Distress
411
Symptoms, a
group that
322
comprises of
patients with
at least one
of the above
disorders
(4681)

Symptom severity category
Rao(row %)
Scott χ2
0-Mild Moderate High
Severe
29.7% 34.2%
21.0% 15.1%
20.8% 34.7%
22.3% 22.1%
22.9%

20.4%

27.4%

29.2%

No use
Monthly or
weekly
Daily or near daily

27.9%
20.5%

22.4%
22.8%

24.5%
25.2%

23.4%
31.5%

8.4%

32.0%

29.7%

29.9%

No use
Monthly or
weekly
Daily or near daily

24.0%
22.5%

30.1%
24.8%

25.2%
21.9%

20.7%
30.7%

17.1%

22.4%

26.2%

34.3%

No use
Monthly or
weekly
Daily or near daily

71.8%
62.2%

11.0%
12.1%

9.1%
13.5%

8.1%
12.1%

62.9%

12.1%

10.3%

14.7%

No use
Monthly or
weekly
Daily or near daily

27.9%
19.9%

27.2%
24.5%

22.7%
24.5%

22.3%
28.7%

13.3%

19.2%

24.7%

42.8%
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p

18.6257

0.0048

7.5733

0.2711

11.2665

0.0805

13.5699

0.0348

61.4618

<.0001

Table 3. Unadjusted ordinal logistic regression model for association between cannabis use
frequency and increasing levels of symptom severity (zero-mild, moderate, high and severe)
Disorder
Variable
OR (95% CI)
p
Panic Disorder
Cannabis use frequency
No use
1.00
--Monthly or weekly
1.508 (1.011, 2.248) 0.0439
Daily or near daily
2.058 (1.276, 3.320) 0.0034
Panic Disorder with Cannabis use frequency
Agoraphobia
No use
1.00
--Monthly or weekly
1.515 (0.844, 2.719) 0.1610
Daily or near daily
1.782 (0.897, 3.539) 0.0976
Social Anxiety
Cannabis use frequency
Disorder
No use
1.00
--Monthly or weekly
1.359 (0.884, 2.090) 0.1600
Daily or near daily
1.808 (1.133, 2.885) 0.0136
Generalized
Cannabis use frequency
Anxiety Disorder
No use
1.00
--Monthly or weekly
1.450 (1.072, 1.961) 0.0163
Daily or near daily
1.954 (1.421, 2.686) <.0001
Anxious-Distress
Cannabis use frequency
Symptoms, a group
No use
1.00
--that comprises of
Monthly or weekly
1.488 (1.194, 1.855) 0.0005
patients with at
Daily or near daily
2.578 (1.928, 3.448) <.0001
least one of the
following: panic
disorder without
agoraphobia, panic
disorder with a
agoraphobia, social
anxiety disorder,
and generalized
anxiety disorder
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Table 4. Adjusted ordinal logistic regression model for relationship between cannabis use
frequency and increasing symptom severity categories (zero/none, low, moderate, and severe)
Disorder
Variable*
OR (95% CI)
p
Panic Disorder
Cannabis use frequency
No use
1.00
--Monthly or weekly
1.449 (0.977, 2.150)
0.0648
Daily or near daily
1.694 (1.041, 2.755)
0.0341
Ever prescribed medicine for
disorder
No
1.00
--Yes
1.504 (1.199, 1.888)
0.0006
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or
any other professional
No
1.00
--Yes
1.531 (1.183, 1.981)
0.0014
Race/ethnicity
White
1.00
--Black
1.656 (1.143, 2.399)
0.0082
Native
1.198 (0.458, 3.136)
0.7097
Asian
1.035 (0.509, 2.105)
0.9239
Hispanic
1.567 (1.087, 2.258 )
0.0233
Age
1.504 (1.058, 2.138)
0.0166
Education
Less than high school
1.00
--High school or equivalent
0.927 (0.594, 1.446)
0.7357
At least some college
0.731 (0.455, 1.173)
0.1916
At least some graduate school 0.508 (0.295, 0.876)
0.0153
Panic Disorder with Cannabis use frequency
Agoraphobia
No use
1.00
--Monthly or weekly
1.063 (0.541, 2.086)
0.8580
Daily or near daily
1.702 (0.833, 3.478)
0.1416
Ever prescribed medicine for
disorder
No
1.00
--Yes
2.610 (1.504, 4.529)
0.0009
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or
any other professional
No
1.00
--Yes
1.597 (1.008, 2.531)
0.0464
Race/ethnicity
1.00
--2.716 (1.332, 5.539)
0.0068
White
Black
4.829 (1.370, 17.024) 0.0151
8

Social Anxiety
Disorder

Generalized
Anxiety Disorder

Native
Asian
Hispanic
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school
Cannabis use frequency
No use
Monthly or weekly
Daily or near daily
Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or
any other professional
No
Yes
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school
Cannabis use frequency
No use
Monthly or weekly
Daily or near daily
Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or
any other professional
No
Yes
Age
Education
Less than high school
High school or equivalent
At least some college
9

3.588 (1.259, 10.231)
1.763 (0.866, 3.588)

0.0176
0.1158

1.00
0.649 (0.343, 1.229)
0.449 (0.236, 0.853)
0.212 (0.085, 0.524)

--0.1809
0.0153
0.0011

1.00
1.317 (0.853, 2.031)
1.535 (0.958, 2.457)

--0.2111
0.0741

1.00
2.269 (1.626, 3.165)

--<.0001

1.00
1.510 (1.114, 2.046)

--0.0084

1.00
0.799 (0.465, 1.372)
0.604 (0.401, 0.909)
0.365 (0.229, 0.582)

--0.4120
0.0163
<.0001

1.00
1.218 (0.898, 1.653)
1.434 (1.042, 1.972)

--0.2023
0.0271

1.00
1.760 (1.453, 2.132)

--<.0001

1.00
2.543 (1.889, 3.422)
0.982 (0.976, 0.988)
1.00
1.103 (0.839, 1.450)
0.771 (0.608, 0.978)
0.658 (0.497, 0.872)

--<.0001
<.0001
--0.4774
0.0324
0.0039

Anxious-Distress
Symptoms, a group
that comprises of
patients with at
least one of the
following: panic
disorder without
agoraphobia, panic
disorder with a
agoraphobia, social
anxiety disorder,
and generalized
anxiety disorder

At least some graduate school
Cannabis use frequency
No use
Monthly or weekly
Daily or near daily

Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or
any other professional
No
Yes
Race/ethnicity
White
Black
Native
Asian
Hispanic
Age
Gender
Female
Male
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school

1.00
1.297 (1.022, 1.645)
2.090 (1.510, 2.894)

--0.0325
<.0001

1.00
2.101 (1.787, 2.471)

--<.0001

1.00
3.416 (2.860, 4.080)

--<.0001

1.00
1.193 (0.972, 1.464)
1.642 (1.095, 2.461)
1.432 (1.017, 2.017)
0.988 (0.831, 1.174)
0.989 (0.984, 0.993)

--0.0906
0.0168
0.0400
0.8855
<.0001

1.00
0.844 (0.736, 0.967)

--0.0152

1.00
1.026 (0.824, 1.279)
0.714 (0.571, 0.894)
0.517 (0.387, 0.691)

--0.8144
0.0036
<.0001

*controlling variables were omitted from the final model via backwards selection if they did not
significantly contribute to prediction value (p<(α=.05)).
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Table 5. Unadjusted multiple linear regression model for relationship between ln(past year
symptom count) and cannabis use frequency
Disorder
Variable
Adjusted β (SE)
p
Panic Disorder
Cannabis use frequency
No use
Reference
--Monthly or weekly
0.077 (0.043)
0.0785
Daily or near daily
0.059 (0.030)
0.0559
Panic Disorder with Cannabis use frequency
Agoraphobia
No use
Reference
--Monthly or weekly
0.060 (0.029)
0.0459
Daily or near daily
0.084 (0.030)
0.0065
Social Anxiety
Cannabis use frequency
Disorder
No use
Reference
--Monthly or weekly
0.048 (0.043)
0.2641
Daily or near daily
0.095 (0.048)
0.0500
Generalized
Cannabis use frequency
Anxiety Disorder
No use
Reference
--Monthly or weekly
0.062 (0.022)
0.0050
Daily or near daily
0.103 (0.020)
<.0001
Anxious-Distress
Cannabis use frequency
Symptoms, a group
No use
Reference
--that comprises of
Monthly or weekly
0.308 (0.097)
0.0019
patients with at
Daily or near daily
0.715 (0.121)
<.0001
least one of the
following: panic
disorder without
agoraphobia, panic
disorder with a
agoraphobia, social
anxiety disorder,
and generalized
anxiety disorder
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Table 6. Adjusted multiple linear regression model for relationship between ln(past year
symptom count) and cannabis use frequency (N= 4689)
Disorder
Variable
Adjusted β (SE)
p
Panic Disorder
Cannabis use frequency
No use
Reference
--Monthly or weekly
0.051 (0.025)
0.0431
Daily or near daily
0.036 (0.041)
0.3824
Ever prescribed medicine for
disorder
No
Reference
--Yes
0.081 (0.016)
<.0001
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or any
other professional
No
Reference
--Yes
0.070 (0.017)
<.0001
Race/ethnicity
White
Reference
--Black
0.071 (0.024)
0.0047
Native
0.061 (0.066)
0.3555
Asian
0.020 (0.045)
0.6641
Hispanic
0.068 (0.024)
0.0064
Age
-0.002 (0.001)
0.0015
Education
Less than high school
Reference
--High school or equivalent
-0.028 (0.025)
0.2504
At least some college
-0.061 (0.025)
0.0167
At least some graduate school
-0.104 (0.030)
0.0006
Panic Disorder
Cannabis use frequency
with Agoraphobia
No use
Reference
--Monthly or weekly
0.026 (0.031)
0.4084
Daily or near daily
0.064 (0.028)
0.0246
Ever prescribed medicine for
--disorder
Reference
<.0001
No
0.026 (0.031)
Yes
Race/ethnicity
White
Reference
--Black
0.067 (0.042)
0.1186
Native
0.103 (0.045)
0.0238
Asian
0.143 (0.103)
0.1705
Hispanic
0.033 (0.034)
0.3347
Education
Reference
---0.035 (0.034)
0.3077
Less than high school
High school or equivalent
-0.086 (0.031)
0.0073
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Social Anxiety
Disorder

Generalized
Anxiety Disorder

At least some college
At least some graduate school
Cannabis use frequency
No use
Monthly or weekly
Daily or near daily
Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or any
other professional
No
Yes
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school
Cannabis use frequency
No use
Monthly or weekly
Daily or near daily
Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or any
other professional
No
Yes
Race/ethnicity
White
Black
Native
Asian
Hispanic
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school
13

-0.180 (0.047)

0.0002

Reference
0.025 (0.034)
0.051 (0.037)

0.4745
0.1702

Reference
0.130 (0.025)

--<.0001

Reference
0.068 (0.024)

--0.0059

Reference
-0.062 (0.038)
-0.112 (0.031)
-0.181 (0.037)

--0.1019
0.0006
<.0001

Reference
0.055 (0.021)
0.082 (0.020)

--0.0096
<.0001

Reference
0.092 (0.013)

--<.0001

Reference
0.134 (0.019)

--<.0001

Reference
0.029 (0.016)
0.056 (0.040)
0.071 (0.035)
0.030 (0.018)

--0.0768
0.1600
0.0464
0.0917

Reference
0.024 (0.023)
-0.012 (0.020)
-0.042 (0.025)

--0.2932
0.5389
0.1001

Anxious-Distress
Cannabis use frequency
Symptoms, a
No use
group that
Monthly or weekly
comprises of
Daily or near daily
patients with at
least one of the
following: panic
disorder without
agoraphobia, panic
disorder with a
agoraphobia, social
anxiety disorder,
and generalized
anxiety disorder
Ever prescribed medicine for
disorder
No
Yes
Sought help from a private
physician, psychiatrist,
psychologist, social worker, or any
other professional
No
Yes
Race/ethnicity
White
Black
Native
Asian
Hispanic
Age
Education
Less than high school
High school or equivalent
At least some college
At least some graduate school

Reference
0.083 (0.033)
0.193 (0.045)

--0.0138
<.0001

Reference
0.245 (0.024)

--<.0001

Reference
0.375 (0.027)

--<.0001

Reference
0.059 (0.029)
0.180 (0.052)
0.089 (0.046)
0.001 (0.026)
-0.004 (0.001)

--0.0490
0.0007
0.0568
0.9890
<.0001

Reference
-0.013 (0.034)
-0.119 (0.034)
-0.216 (0.042)

--0.7112
0.0005
<.0001

*controlling variables were omitted from the final model via backwards selection if they did not
significantly contribute to prediction value (p<(α=.05)).
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BACKGROUND & RATIONALE
Self-medication for existing anxiety and mood disorders is quite common in adults
(Bolton 2009). Cannabis is a popular drug of choice for relief from a variety of conditions
including migraines, everyday stresses and sleeping difficulties resulting from insomnia as well
as both disordered and non-disordered or “common” anxiety (Ogborne 2000; Bonn-Miller et al.,
2007; Buckner et al., 2008). According to a review by Wittchen et. al. (2007), a number of
prospective studies have shown that the presence of highly symptomatic anxiety disorders in
adolescence significantly predicts cannabis use later in adulthood.
While people report reduced anxiety as their primary motivation for using cannabis,
paradoxically, acute anxiety is the most common adverse effect of cannabis use. When taken in
high doses, [(>5 mg oralD9-tetrahydrocannabinol (D9-THC) for a man of average weight],
cannabis can cause intense fear, anxiety, panic and phobic attacks (Hall and Solowij, 1998;
Thomas, 1993; Tournier et al., 2003). This conflict in evidence may be mediated by the
observation that the side effects of cannabis appear to be dose-dependent. For example, low
doses of the cannabinoid receptor agonists, nabilone (Onaivi et al., 1990) and D9-THC
(Berrendero and Maldonado, 2002) have anxiolytic-like effects in laboratory rodents, whereas
higher doses produce anxiogenic behaviour and activate the hypotalamic–pituitary–
adrenocortical axis (Berren-dero and Maldonado, 2002; Giuliani et al., 2000; Viveros et al.,
2005). This necessitates a closer look at the potential therapeutic effects of cannabis selfmedication through the lens of frequency and dose of use.
Furthermore, the existing body of literature seems to focus on the onset of panic disorders
or other side effects as an association with cannabis use, but does little to address how possible
concomitant cannabis use affects symptom presentation in already-diagnosed patients. There is
currently little known about how cannabis interacts with prescription medication in symptom
15

abation. The present project aims to take a closer look at adults with a history of DSM-5
diagnosed panic, social anxiety, or generalized anxiety disorder, their prescribed (non-cannabis)
medication use, cannabis use status, and associated symptom severity. For example: does selfmedication with cannabis in lieu of prescribed medication abate symptoms? If a person is already
taking anxiety medication, does simultaneously using cannabis have even greater symptom
reduction than using prescriptions alone? Or does it have no additional benefit? We are hoping to
compare symptom presentation of groups of people based on cannabis use status while
controlling for prescribed medication status. Additionally, we investigate the plausibility of a
frequency-response relationship of symptom severity in conjunction with frequency of cannabis
use.

METHODS
Survey Instrument
The National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARCIII) was sponsored, designed and directed by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA). The NESARC-III is cross-sectional, based on a nationally representative
sample of the civilian population of the United States.
The NESARC-III contains data from a well-characterized population sample, containing
demographic data as well as various information such as lifetime and past 12 month history of
chronic diseases/disorders/disabilities, substance use attitudes, and self-reports of symptoms.
Data on cannabis use and frequency is available for both lifetime and past year use. Particular
focus will be put on patients who have current (within the past year) active diagnoses and their
current symptoms, as their experiences may be more salient and more accurately reported while
completing the NESARC-3 survey. All patients are non-institutionalized adults ages 18 years
and over residing in the US.
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Full survey methodology can be found on the NIH website.

Study Population
In total, 36,309 adults were captured with the NESARC-III survey. In this study, I
focused on 4,689 individuals who had a lifetime history of DSM-5 diagnosed anxiety-related
disorders, including panic disorder without agoraphobia (n= 1451), panic disorder with
agoraphobia (n=362), social anxiety disorder (n=1255), and generalized anxiety disorder (n=
2708) in the US. Of this anxiety-related subset, 825 individuals had a lifetime history of 2 or
more of the disorders of interest.

Measures
Independent Variables
Cannabis Use. The primary independent variable of interest is current (defined as pastyear) use of cannabis. Past year cannabis use was assessed by the NESARC-III questions that ask
“Have you ever used cannabis?” and if so, “Have you used cannabis within the last 12 months?”.
Based off of these questions, past year cannabis use is coded as “Yes”, “No”, or “Missing”.
A variable for cannabis use frequency was also derived from a NESARC-III question that
asked, “How often do you use cannabis?”. The original question had 13 response levels, ranging
from never to daily. We chose to collapse these levels into 3: never, monthly or weekly, daily or
more days than not. The reasoning behind these new categorizations is that 1.) a large proportion
of people choose not to use cannabis or choose not to reveal their usage out of stigma and 2.)
daily or near daily users may have an additional motive for cannabis usage, implying that they
are more likely to be using it as a coping mechanism or self-medication, whereas recreational
users likely are not reliant on continuous use for symptom management.
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Medication status. The medication status variable reflects whether or not a patient has
ever been prescribed medication for their specific panic-anxiety disorder by a physician.
Possible confounders. There remains a possibility that having more than 1 panic-anxiety
disorder may non-linearly increase the magnitude of symptom presentation. To address this, we
looked at comorbidity, creating a variable that captured how many conditions (1-3 out of panic
disorder without agoraphobia, panic disorder with agoraphobia, social anxiety disorder, and
general anxiety disorder) an individual met lifetime for.
Additionally, it is common practice for patients suffering from panic-anxiety symptoms
to manage their symptoms with talk therapy with or without medication. Although the NESARCIII survey does not specifically address psychotherapy in its probing for each disorder, we
attempt to control for this by creating a variable that reflects whether or not a patient has sought
help for their condition from a private physician, psychiatrist, psychologist, social worker, or any
other professional.
Demographics. We included the following demographic variables: age, sex, race, marital
status, and educational attainment.
Age was left as its original continuous variable.
Race was included as a categorical variable, with its levels being: White, Black, NativeAmerican, Asian, and Hispanic.
Marital status was collapsed from its original categorical variable, to include 4 levels:
Never Married, Married/Common-Law Marriage, Separated/Divorced and Widowed.
Educational attainment was collapsed from its original 14 level variable into a 4 level
ordinal categorical variable, categorized as less than high school, high school or equivalent, some
college up to a bachelor's, or at least some graduate school.
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Dependent Variables
Symptom severity. Under a separate section for each disorder, the NESARC-III survey
asks questions akin to “Do you have an intense fear of using public transportation?” and “Do you
often feel detached from things around you?” in an effort to measure how symptomatic the
respondents are during a specified time period. These questions are directly referenced from the
DSM-5 diagnostic criteria for their respective disorders (American Psychiatric Association,
2013). We define “current symptoms” as any symptom occurring within the past year (last 12
months). First, within each disorder, for this time period, we tallied up the number of symptom
questions to which patients responded “Yes”; “No” responses did not contribute to the count, and
“Missing” responses were few enough in number to be safely excluded without fear of
disproportionality or bias. This symptom count variable is treated as continuous when used for
linear regression modeling (see “Data Analysis”). A composite version of this variable was
created by simply summing up all symptom tallies for all disorders of interest; this allencompassing symptom severity variable is meant to allow us to assess symptom presentation
for all patients within our panic-anxiety population, regardless of formal DSM-5 diagnosis. This
is done to account for the fact that while an individual can be clinically diagnosed with one
disorder, they may still experience some symptoms that are associated with another, to a lesser
extent (e.g., someone with a generalized anxiety diagnosis can still experience panic attacks, but
not to the magnitude that they would also meet panic disorder DSM-5 criteria).
Secondly, we converted our symptom count variables to reflect an ordinal categorization
of severity for use in chi-square and ordinal logistic regression (see “Data Analysis”). The
ordinal symptom severity variables all have 4 levels: none-mild, moderate, high, and severe
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based on quartiles. The count distribution was divided into quartiles to populate the none-mild,
moderate, high and severe levels respectively.

Data Analysis
χ2 Tests
As part of exploratory analysis, unadjusted χ2 tests were performed for each disorder, as
well as the entire sample of people who have any of the 4 disorders, looking for possible
bivariate associations between symptom severity categories (zero/none, low, moderate, high and
severe) and factors of interest. Bivariate analysis was also undertaken between symptom severity
category and categorical demographic variables or other confounders.

Ordinal Logistic Regression
Due to the ordinal nature of the symptom severity levels (i.e., zero/none, low, moderate,
high and severe), we investigated the predictive power of cannabis use frequency and medication
status via ordinal logistic regression. In addition, other possible predictor variables and possible
confounders were added into the adjusted model.

Multiple Linear Regression
We ensured that all symptom severity counts were normally distributed by transforming
all of them into their natural logarithms.
The original symptom severity variables turned out to have counts high enough for them
to be treated as continuous variables. Due to concerns that turning a continuous variable into a
categorical one would abolish some of the nuance of the data, we decided to build both
unadjusted and adjusted models to predict symptom severity based on a number of independent
variables.
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Statistical Plan
I began by using descriptive statistics to summarize the characteristics of the sample, both
overall and by disorder. Then, I started looking for possible bivariate associations between
frequency of cannabis use and symptom severity for each disorder (as well as the whole anxiousdistress subset, for individuals who have a lifetime history of at least 1 of the 4 disorders of
interest) using a chi square test.
Subsequently, I used two modeling approaches:
1.) For a 4-level ordinal outcome (the levels of symptom severity ranging from “nonemild” to “severe”), I used ordinal logistic regression. Both the unadjusted and adjusted odds
ratios and their respective 95% confidence intervals were calculated. Multivariable models
adjusted for prescription medication status, whether or not an individual sought professional help
within the last 12 months, age, gender, race, and educational status.
2.) For a continuous symptom score, I used linear regression. Given skewed, non-normal
distributions for some of the disorder-specific scores, I transformed my symptoms scores to their
natural logarithms. Again, multivariable models adjusted for prescription medication status,
whether or not an individual sought professional help within the last 12 months, age, gender, race,
and educational status.
All analyses were performed using SURVEY procedures in SAS to account for the
multistage probability sample survey design and weighting. Unweighted N’s are presented
throughout.

RESULTS
Sample Description
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Overall, 15.72% of patients have used cannabis in some form during the last 12 months
(see Table 1). Among the disorders, panic disorder with agoraphobia patients have the highest
proportion of cannabis users, at 21.55%.
Across disorders, the proportions of people with a history of prescription medication use
range from panic disorder with agoraphobia patients with the highest at 80.11% to generalized
anxiety disorder patients with the lowest at 24.59%.
Additionally, the majority of our study population is female. Across all panic-anxiety
disorders, 63.82% to 76.52% of patients are female.
Interestingly, people who are diagnosed with panic disorder with agoraphobia are more
likely to also be diagnosed with the other disorders of interest (save panic disorder alone);
27.62% of this patient group has a lifetime history of both social anxiety and generalized anxiety.
χ2 test for association between cannabis use and symptom severity categories
Increasing frequency of cannabis use is associated with increasing symptom severity,
although not statistically significant for panic disorder with agoraphobia and social anxiety
disorder and marginally significant at p<0.10 for panic disorder without agoraphobia,
generalized anxiety disorder, and the combined patient pool for all disorders of interest (see
Table 2).

Unadjusted ordinal logistic regression model for association between cannabis use
frequency and increasing levels of symptom severity
Consistent with findings in Table 2, we find that increasing frequency of cannabis use is
associated with increasing odds of more severity symptom level (p<.05) for all disorders except
panic disorder with agoraphobia (see Table 3). However, we do see one discrepancy: now, social
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anxiety patients who use cannabis on a daily or near daily basis have 1.808 times the odds of
higher symptom presentation as people who are abstinent (p=0.0136).

Adjusted ordinal logistic regression model for relationship between cannabis use frequency
and increasing levels of symptom severity
There is no significant difference in the odds of being in a higher level of panic with
agoraphobia, or social anxiety symptom severity between patients who use cannabis at any
frequency and non-users (see Table 4; all p>(α=.05)).
GAD patients who use cannabis more days than not have higher odds of having a higher
level of symptom severity than non-cannabis users, given that all of the other variables remain
constant. Surprisingly, the same is not true for infrequent cannabis consumers; GAD patients
who intake cannabis on weekly or monthly basis do not have a significantly different odds of
higher symptom severity than non-users (p=0.2023). Similar results were found for panic
disorder without agoraphobia patients, for which regular users have higher symptom severity
(p=0.0341) compared to abstinent patients. Yet, infrequent cannabis users do not have
significantly different odds of higher panic disorder severity (p=0.0648).
In an effort to look at anxiety-distress symptoms in general, non-specific to any disorder
and not contingent on a person’s fulfillment of all of the DSM-5 criteria for diagnosis, we
combined all of the disorders into one patient population. We found similar results in that a
cannabis user of any frequency has increased anxious-distress symptom severity compared to
non-users, given all of the other variables in the model are held constant (p< 0.0001).
There appear to be some confounding, complex underlying relationships between
prescription medication status, age, race, and education that simultaneously account for
differences in symptom severity. People have been prescribed medication and those who have
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sought professional help for their disorder show increased symptom severity compared to those
who did not. Consistent across all disorder-specific analyses, educational attainment seems to be
a major contributor in particular. Beyond high school, people who have pursued higher
education, be it in baccalaureate or graduate studies, have lower odds of presenting with higher
levels or buckets of anxious-distress symptoms than non-high school graduates (all p<(α=.05)).
Specifically, graduate students have the lowest odds of higher symptom severity.
The proportional odds assumption was not met for any of the ordinal logistic tests
described above. The Score Tests for the Proportional Odds Assumption were highly significant,
which indicates that the cumulative logit model might not adequately fit the data. In addition,
concerns that categorizing the symptom presentation tallies (which have high enough counts to
possibly be considered continuous) into arbitrary buckets might remove the nuance of patient
responses prompted us to fit a multiple linear regression model.

Unadjusted multiple linear regression model for relationship between past year symptom
count and cannabis use frequency
Generally, we found a similar pattern of results found when symptom severity is modeled
as a continuous outcome; increasing frequency of use is associated with higher symptom
presentation (see Table 5). However, one major difference is that the added nuance has now
allowed us to see a significant difference in symptom severity among all levels of cannabis use
within the panic disorder without agoraphobia population. Additionally, panic disorder without
agoraphobia patients now display no difference in symptom severity, regardless of level of
cannabis use.
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Adjusted multiple linear regression model for relationship between past year symptom
count and cannabis use frequency
In general, the adjusted model shows the same pattern of significance as the unadjusted
model; higher frequency of cannabis use is associated with higher symptom presentation across
all disorders except for social anxiety (see Table 6). This is seen most robustly for generalized
anxiety disorder.
Pure panic disorder patients who partake in cannabis on a weekly or monthly basis have a
5.2% more symptoms on average than those who are abstinent, holding all other variables
constant (eβ =1.052). Unexpectedly, daily or near daily users do not have a significantly different
mean symptom count than those who are abstinent.
In contrast, the exact opposite results for cannabis frequency levels hold true for patients
who have a history of panic disorder with agoraphobia.
Similar results were found when we looked at our entire patient population as a whole,
regardless of which of the 4 conditions of interest any individual was affected by. Those who
consumed cannabis on a daily or nearly daily basis presented with 21.3% more symptoms on
average compared to those who are abstinent (eβ =1.213) after controlling for confounders.
Again, after adjustment, patients whose cannabis intake varies from once weekly or monthly had
symptom severities that were on average 8.6% higher compared to non-cannabis users (eβ
=1.06).
The importance of prescription medication status, seeking help from professionals, and
educational attainment is evident. Not only are they significant predictors of symptom severity,
but they also modulate cannabis use’s predictive value across all disorders. This is especially true
in the case of social anxiety disorder, as all of cannabis use frequency’s effect on symptom count
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has been mitigated after controlling for confounders. Sufferers of social anxiety do not have
significantly different mean symptom counts, regardless of cannabis use frequency.
As for educational attainment, people who choose to pursue higher learning after high
school, on average, have fewer anxious-distress symptoms than people who did not graduate
from high school.

DISCUSSION
In general, we find that cannabis use is associated with higher panic-anxiety symptom
severity across panic disorder without agoraphobia, generalized anxiety disorder, and people
with combined anxious-distress diagnoses after controlling for prescription medication status and
professional help seeking. Worth noting is that we found no dose-response relationship for
frequency of cannabis use. Being an infrequent user (defined as once monthly or weekly) is not
significantly different than being a daily user in terms of unique symptom presentation. This
means that increasingly higher cannabis use does not necessarily induce increasingly more
severe anxiety or distress. Rather, it seems that once an individual’s cannabis use crosses over a
certain threshold, symptom presentation increases. For some disorders, this is an all-or-none
phenomenon; any cannabis use is associated with more severe symptoms than staying abstinent.
For others, only daily users present with higher symptoms than non-users. The sole divergence to
this conclusion is that panic without agoraphobia patients who use infrequently seem to have
more severe symptoms than non-users and daily users.
Although cannabis is still registered as a Schedule 1 drug federally, a wave of state
initiatives has decriminalized the drug in large swathes of the country, increasing the proportion
of recreational users due to ease of access. Former restrictions limited the user pool to medicinal
users to some degree, based on effectiveness of enforcement in certain regions. With the current
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upswing of recreational marijuana legalization in the United States, new legislation will expand
access to cannabis to a wider population.
This will usher in more widespread implications for public health, particularly because up
to 33.7% of the population is affected by an anxiety disorder during their lifetime (Bandelow,
2013). Panic disorder with or without agoraphobia, social anxiety disorder, and generalized
anxiety disorder are the most prevalent anxiety disorders and are associated with immense health
care costs. Due to the high burden of disease, many of these patients choose to self-medicate
using cannabis. We found that cannabis use resonates with higher symptom presentation,
regardless of frequency. However, we see from the parameter coefficients that the difference
between users and non-users is often small and not necessarily clinically relevant: only 1 or 2
symptoms. Although this provides some insight if we define symptom severity as the number of
unique symptom presentations, we should also consider the magnitude of impact these additional
one or two symptoms may have on patients’ quality of life. For example, how life-changing is it
if you develop sweaty palms? How about compared to developing excessive fear of social
situations? However, barring the most extreme symptoms, cannabis use does not seem to cause
excessive harm to the point of drastically reduced functioning. In fact, based off the distribution
tables and the fact that more symptomatic patients are more likely to seek help or use
prescription medication, it seems entirely possible that the same patients would try to selfmedicate using cannabis in an attempt to mitigate some of the more dehabilitating symptoms.
Contrary to current literature, age is not a major contributing factor for higher symptom
presentation for any of the 4 anxiety disorders besides panic disorder, for which our patient
population skews slightly young (Patton et. al., 2002). As cannabis policy reform moves forward,
one of the greatest concerns legislators and parents have is that legalization will increase
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cannabis use among young people, and in particular, initiate adolescent users who would not
otherwise have used cannabis. In fact, even legal states such as Colorado and Massachusetts have
an age threshold of 21 (down from previous restrictions of at least 25 years old for medical
marijuana registration eligibility). However, the raison d’etre for this is rooted, in large part, in
moralistic apprehensions rather than health-related ones. In addition to the null results seen in the
present paper, regular cannabis use that begins in adolescence and continues throughout young
adulthood appears to produce cognitive impairment but the mechanism and reversibility of the
impairment is unclear (Hall, 2015).
As cannabis legislation becomes more permissive, either by lowering the age limit or
expanding access, it is our hope that this will lift some of the restrictions on scientific
investigations, allowing deeper clarity into the relationship between cannabis and health effects.
Directions for future work include further comparisons of how anxious-distress symptoms
severity presents in states with and without permissive cannabis legislation. Additionally, regular
cannabis use has previously been associated with higher risks of developing chronic bronchitis,
as well as higher risks of myocardial infarction in middle-aged adults (Hall, 2015). However,
these effects may also be explained by tobacco use, for which cannabis use has long been
difficult to disentangle from, as most smokers partake in both. Due to the incredibly varied
methods of cannabis consumption (eg. extract vape, oils, regular flower), it may become possible
to isolate or remove confounding factors (eg. minimize the confounding effect of physical
combustion or smoke by studying only tobacco chewers and cannabis extract vapers). Given any
health revelations that elucidate the health risks of cannabis relative to tobacco, this may in turn,
allow us to revisit or revise tobacco laws when compared to cannabis laws and vice versa.
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A major limitation of this analysis lies in the cross-sectional nature of the NESARC-III
survey. Patient responses are captured from a snapshot in time, rather than longitudinally. Of
course, this means that a comparison of prior symptoms to current symptoms may be flawed, as
prior symptoms are self-reported after possibly years of lag, resulting in memory bias.
Additionally, this raises concerns about the actual chronological causality of effects from our
“treatments”, medication status and cannabis use; how can we ascertain if more severe symptom
presentation causes people to seek out medication or self-medicate with cannabis or if cannabis
induces more severe symptoms?
Another potential pitfall is that within the survey definition of “cannabis use”, there is no
differentiation between THC, which may be anxiety-inducing in high doses and CBD, which
may be anxiolytic. This might confound some of the patient responses regarding anxiety
symptoms.
Due to both the social stigma and possible legal ramifications of admitting to cannabis
use in more conservative states, it is possible that our sample has underreported cannabis use.
However, this bias is likely to only inflate the population of non-users and equally affect reported
cannabis use across all other frequencies; social and legal ramifications usually do not
differentiate based on magnitude of consumption.
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